Drugs / Reloxaliase
Reloxaliase
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT03391804 | Jul 2018 → Dec 2019 | primary hyperoxaluria | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02547805 | Sep 2015 → Jan 2017 | nephrolithiasis | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02503345 | Jul 2015 → Aug 2016 | nephrolithiasis | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02289755 | Sep 2014 → Jan 2015 | nephrolithiasis, calcium oxalate | Allena Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03847090 | Aug 2019 → May 2022 | — | Allena Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03456830 | May 2018 → Sep 2019 | — | Allena Pharmaceuticals | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | reloxaliase | “Reloxaliase is an orally administered recombinant enzyme that degrades oxalate along the gastrointestinal tract, thereby preventing its absorption.” PMID 38319254 ↗ May 2022 |
| Known as | ALLN-177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289755 ↗ |
| Known as | Reloxaliasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297818 ↗ |
| Modality | Protein / enzyme biologic | “ALLN-177 is an orally administered form of oxalate decarboxylase.” NCT02547805 ↗ |
| Route | Oral | “ALLN-177 is orally administered oxalate decarboxylase (OxDc).” NCT02289755 ↗ |